Abraxis BioScience Launches Abraxane® in European Union
Initial Product Launch in the UK, Followed by Germany in Q1 2009
Abraxis BioScience Launches Abraxane ® in European Union
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced the launch in the European Union of Abraxane ® Paclitaxel 5 mg/ml powder for suspension for infusion. Abraxane ® is an albumin-bound nanoparticle formulation of paclitaxel. In the EU, Abraxane ® is indicated for the treatment of metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline-containing therapy is not indicated.
“The launch of Abraxane ® in the EU, initially in the UK, is a significant milestone in our program to provide patients across the European continent with a new option for the treatment of metastatic breast cancer,” said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of Abraxis BioScience. “Abraxis BioScience has made significant progress in 2008 in expanding the market reach of Abraxane ® in India, China and the Asia-Pacific region. Our EU launch marks an important entry point in building a truly global presence for Abraxis BioScience as we seek approvals for new indications for Abraxane ® and continue to develop additional advanced medications in our pipeline.”
“In a key Phase III clinical study, Abraxane ® demonstrated statistically significant superiority over solvent-based paclitaxel injection in the clinical endpoints of response rate, progression free survival and overall patient survival in patients treated according to the approved indication, with comparable tolerability,” said Robert Coleman, MBBS, M.D., FRCP, Professor and Honorary Consultant Medical Oncologist at the Cancer Research Centre, Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield. “Given the clinical benefits compared with paclitaxel injection, Abraxane ® should become the paclitaxel therapy of choice for oncologists throughout Europe for the second-line treatment of patients with metastatic breast cancer.”
“Use of Abraxane ® requires no pre-medication as it is not formulated with toxic solvents and is more convenient to administer than solvent-based paclitaxel,” said Prof. Dr. med. Gunter von Minckwitz, Managing Director, German Breast Group Forschungs GmbH, Neu-Isenburg, Germany.
The Department of Health approved a price of 246 pounds per 100 mg vial of Abraxane ® . Following the current launch in the UK, Abraxane ® will be launched in Germany in the first quarter of 2009, followed by additional nations in Europe on a country by country basis.
“We have assembled a solid group of seasoned marketing, regulatory and product support professionals to market this new treatment for women in Europe with metastatic breast cancer,” said Jean-François Gimonet, M.D., Vice President, European Operations of Abraxis BioScience. “This launch lays the foundation for building our organization across Europe and for establishing Abraxis BioScience as an industry leader in the European Union.”
Sales force and commercial services for Abraxis BioScience in the EU will be provided by Innovex, a unit of Quintiles Transnational Corp., which is the leading global commercial solutions provider to the pharmaceutical, biotech and medical device industries.
To date, Abraxane ® has been approved for marketing in 36 countries. In addition to Europe, Abraxane ® recently was launched in Australia in collaboration with Specialised Therapeutics Australia Pty Ltd; in the United Arab Emirates with partner Neobiocon; and, in India with Biocon Limited. The Korean FDA has granted marketing approval for Abraxane ® and the launch in that country is expected in 2009 with Abraxis’ partner Green Cross Corporation. Additionally, approval has been received in China, with an anticipated launch in 2009. Abraxane ® is currently under active review in Japan and Russia.
About Abraxane ®
The Phase III clinical trial upon which European marketing approval was based demonstrated that Abraxane ® nearly doubled the overall target lesion response rate versus solvent-based paclitaxel and achieved a 28 percent improvement in progression-free survival when compared to solvent-based paclitaxel. In addition, time to tumor progression versus solvent-based paclitaxel was significantly prolonged in patients receiving Abraxane®. The tolerability with Abraxane ® and solvent-based paclitaxel was comparable, despite the 50% greater dose of paclitaxel administered as Abraxane ® . Neutropaenia was lower with Abraxane ® compared to solvent-based paclitaxel. Although there was an increase in incidence of grade 3 peripheral neuropathy, time to improvement was improved compared to that reported for solvent-based paclitaxel. No adverse events were reported that were not already known for paclitaxel.
For further information about the approval of Abraxane ® in Europe, please visit http://www.emea.europa.eu/humandocs/Humans/EPAR/Abraxane/Abraxane.htm .
About Innovex
Innovex is the sales and marketing unit of Quintiles Transnational Corp. Innovex is a leading commercial solutions provider that offers sales and marketing services designed to accelerate the success of pharmaceutical, biotechnology and medical device products. Innovex operates in multiple geographies and ensures that high quality sales solutions can be provided where the customer needs them – locally, regionally and across multiple countries. For more information, visit www.innovex.com .
About Quintiles
Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commerzialisation for the biotechnology and healthcare industries. With over 21,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company’s web site at www.qtrn.com .
About Abraxis BioScience
Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound chemotherapeutic compound (Abraxane ® ), which is based on the company's proprietary tumor targeting technology known as the nab TM platform. The first FDA approved product to use this nab TM platform, Abraxane ® , was launched in 2005 for the treatment of breast cancer after the failure of prior chemotherapy for metastatic disease. Abraxis BioScience trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com .
FORWARD-LOOKING STATEMENTS
The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the launch of Abraxane ® in the European Union. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include, without limitation, unexpected safety, efficacy or manufacturing issues with respect to Abraxane ® ; the need for additional data or clinical studies for Abraxane ® ; regulatory developments (domestic or foreign) involving the company’s manufacturing facilities; the market adoption and demand of Abraxane ® , the costs associated with the ongoing launch of Abraxane ® ; the impact of pharmaceutical industry regulation; the impact of competitive products and pricing; the availability and pricing of ingredients used in the manufacture of pharmaceutical products; the ability to successfully manufacture products in a time-sensitive and cost effective manner; the acceptance and demand of new pharmaceutical products; and the impact of patents and other proprietary rights held by competitors and other third parties. Additional relevant information concerning risks can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2007 and in other documents it has filed with the Securities and Exchange Commission.
The information contained in this press release is as of the date of this release. Abraxis BioScience assumes no obligations to update any forward-looking statements contained in this press release as the result of new information or future events or developments.
Taxol® is a registered trademark of Bristol-Myers Squibb Company.
Contact:
Investor and Media Inquiries
Abraxis BioScience, Inc.
Daniel
Saks
Vice President, Investor Relations and Corporate Communications
310.405.7417
or
Pondel
Wilkinson Inc.
Rob Whetstone
310.279.5963
or
Press
Contacts Europe
College Hill
Adam Michael, Cosima Zerdik,
John McIntyre
abraxis@collegehill.com
+44
(0) 20 7457 2020
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom